Luca Palazzo

Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 11

Top Venues

Pathogens (Basel, Switzerland)

eLife

The FEBS journal

Biochemical Society transactions

Institute Experimental Endocrinology and Oncology

Università degli Studi di Napoli Federico II (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Institute Experimental Endocrinology and Oncology Jul 01 2020

Italy

Researcher - CNR Staff Scientist

Institute Experimental Endocrinology and Oncology Jun 01 2019 - Jun 30 2020

Italy

Research Fellow

Institute of Protein Biochemistry Jun 01 2018 - May 31 2019

Italy

Research Fellow

University of Oxford

United Kingdom

Postdoctoral Fellow :: Sir William Dunn School of Pathology

University of Oxford

United Kingdom

Postdoctoral Fellow funded by AIRC :: Sir William Dunn School of Pathology

Università degli Studi di Napoli Federico II

Italy

Postdoctoral Fellow funded by FIRC :: Department of Molecular Medicine and Medical Biotechnology

Education History

Università degli Studi di Napoli Federico II - Jan 20 2011

Italy

PHD :: Department of Cellular and Molecular Biology and Pathology

Università degli Studi di Napoli Federico II - Sep 27 2007

Italy

MSC :: Department of Cellular and Molecular Biology and Pathology

Università degli Studi di Napoli Federico II - Oct 25 2005

Italy

BSC :: Department of Cellular and Molecular Biology and Pathology

Publications

Giuliana Catara, Rocco Caggiano, Luca Palazzo
The DarT/DarG Toxin-Antitoxin ADP-Ribosylation System as a Novel Target for a Rational Design of Innovative Antimicrobial Strategies. Pathogens (Basel, Switzerland) 12 (2) (2023)
Giuliana Catara, Rocco Caggiano, Luca Palazzo
The DarT/DarG Toxin-Antitoxin ADP-Ribosylation System as a Novel Target for a Rational Design of Innovative Antimicrobial Strategies. Pathogens (Basel, Switzerland) 12 (2) (2023)
Giuliana Catara, Rocco Caggiano, Luca Palazzo
The DarT/DarG Toxin-Antitoxin ADP-Ribosylation System as a Novel Target for a Rational Design of Innovative Antimicrobial Strategies. Pathogens (Basel, Switzerland) 12 (2) (2023)
Giuliana Catara, Rocco Caggiano, Luca Palazzo
The DarT/DarG Toxin-Antitoxin ADP-Ribosylation System as a Novel Target for a Rational Design of Innovative Antimicrobial Strategies. Pathogens (Basel, Switzerland) 12 (2) (2023)
Palmiro Poltronieri, Angela Celetti, Luca Palazzo
Mono(ADP-ribosyl)ation Enzymes and NAD+ Metabolism: A Focus on Diseases and Therapeutic Perspectives. Cells 10 (1) (2021)
Marcin Józef Suskiewicz, Luca Palazzo, Rebecca Hughes, Ivan Ahel
Progress and outlook in studying the substrate specificities of PARPs and related enzymes. The FEBS journal 288 (7) (2020)
Francesco Morra, Francesco Merolla, Ida Picardi, Daniela Russo, Gennaro Ilardi, Silvia Varricchio, Federica Liotti, Roberto Pacelli, Luca Palazzo, Massimo Mascolo, Angela Celetti, Stefania Staibano
CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC. Cancers 11 (10) (2019)
Luca Palazzo, Orsolya Leidecker, Evgeniia A Prokhorova, Helen Dauben, Ivan Matic, Ivan Ahel
Serine is the major residue for ADP-ribosylation upon DNA damage. eLife 7 (2018)
Luca Palazzo, Ivan Ahel
PARPs in genome stability and signal transduction: implications for cancer therapy. Biochemical Society transactions 46 (6) (2018)
Pietro Fontana, Juan Jose Bonfiglio, Luca Palazzo, Edward Bartlett, Ivan Matic, Ivan Ahel
Serine ADP-ribosylation reversal by the hydrolase ARH3. eLife 6 (2017)
Luca Palazzo, Andreja Mikoč, Ivan Ahel
ADP-ribosylation: new facets of an ancient modification. The FEBS journal 284 (18) (2017)

Luca Palazzo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Luca Palazzo